How immune cells help antibodies kill cancer and infected cells
Official title: The immune regulation of macrophage antibody dependent cellular phagocytosis
Funded at South Dakota State University · NIH-10828398 · Data updated 2026-11-12
This study is looking at how certain immune cells called macrophages can help make antibody treatments better for people with autoimmune diseases and cancer, so we can understand why some patients do well with these treatments while others don’t.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | South Dakota State University NIH-funded |
| Lab location | 1 site (Brookings, United States) |
| Project start | July 10, 2020 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $372,801 |
| NIH project number | 5U01AI148153-05 |
| Project ID | NIH-10828398 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with autoimmune diseases or cancers who are receiving or considering antibody-based therapies.
✕Less likely to help
Patients who do not have autoimmune diseases or cancers may not benefit from this research.
What this research studies
This research investigates how macrophages, a type of immune cell, can enhance the effectiveness of therapeutic antibodies used to treat autoimmune diseases and cancers. By examining how these cells interact with antibodies in different environments, the study aims to understand why some patients respond well to treatments while others do not. The researchers will use advanced techniques, including CRISPR gene editing and transcriptomics, to identify the mechanisms that control macrophage function and improve antibody-mediated cell destruction. This could lead to more effective therapies for patients with varying responses to current treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies that enhance the effectiveness of antibody treatments for patients with autoimmune diseases and cancers.
How similar studies have gone: Previous research has shown that enhancing macrophage function can improve the effectiveness of antibody therapies, indicating potential for success in this approach.
Where this research is happening
-
South Dakota State University
Brookings, United States Active
Researchers
- Principal investigator: Hoppe, Adam David — South Dakota State University
- Study coordinator: Hoppe, Adam David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.